# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infecti...
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.13...
National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA, to participate in the Uni...